Bioclinica, a provider of scientific-enabled medical imaging, eHealth, and patient-centric solutions supporting clinical research, has acquired MDDX Research & Informatics, adding cloud research image management and submission technologies.

MDDX’s cloud-based image submission technology will become a major part of Bioclinica’s SMART solution (Submit, Manage, Analyze, Report, and Transfer), a suite of centralized medical imaging services designed to manage the imaging process from image receipt and analysis to regulatory submission.

The MDDX platform is FDA 21 CFR Part 11 compliant. The platform, powered by artificial intelligence and machine-learning technologies, integrates more than 1,500 screening and de-identification rules to detect image issues and automatically de-identify any standard image type. An online hosting environment offers real-time access to imaging data along with audit trail transparency.

Bioclinica president and chief executive officer, John Hubbard, Ph.D., said, “Combining the MDDX technology suite with Bioclinica, including advanced cloud research image management and services, is a perfect match, especially for sponsors who want the assurance that the critical medical imaging component of a clinical trial is managed efficiently, accurately, and reliably, regardless of where the trial is held in the world. Making the sophisticated and proven MDDX technology the backbone of our medical image submission solution means that Bioclinica customers can now rely on a unique combination of the industry’s most experienced medical imaging professionals and the most advanced imaging technologies.”

MDDX founder and chief designer Dan Gebow, Ph.D., along with his team of image data technologists and software engineers, will head up research image management at Bioclinica.
Dr. Gebow said, “Bioclinica has been the hands-down industry leader in imaging and scientific integrity for clinical trials. Together with MDDX’s leading-edge technologies we will accelerate the pace of disease discovery, treatment and medical devices while opening new possibilities for cross-trial image data insights.”